---
title: "Akeso Inc. Announces Positive Results from Global Phase III HARMONi Trial of Ivonescimab, Demonstrating Improved Overall Survival in Lung Cancer Patients"
description: "Akeso, Inc. announced positive results from the global Phase III HARMONi trial of ivonescimab, showing improved overall survival in lung cancer patients. The trial revealed a hazard ratio of 0.78 and "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/256269429.md"
published_at: "2025-09-07T10:09:35.000Z"
---

# Akeso Inc. Announces Positive Results from Global Phase III HARMONi Trial of Ivonescimab, Demonstrating Improved Overall Survival in Lung Cancer Patients

> Akeso, Inc. announced positive results from the global Phase III HARMONi trial of ivonescimab, showing improved overall survival in lung cancer patients. The trial revealed a hazard ratio of 0.78 and a median overall survival of 17.0 months for patients receiving ivonescimab, compared to 14.0 months for those on placebo. The findings indicate consistent benefits across subgroups. Additionally, the HARMONi-A study in China has reached its overall survival clinical endpoint, with results to be shared at future conferences.

Akeso, Inc. has announced updated results from the global Phase III HARMONi clinical trial of ivonescimab, a PD-1/VEGF bispecific antibody. This update, shared by Summit Therapeutics, Akeso’s global partner, during the 2025 World Conference on Lung Cancer, highlights longer-term follow-up data of western patients showing an improving trend in overall survival (OS). The analysis revealed a hazard ratio of 0.78 with a nominal p-value of 0.0332. The median OS for western patients receiving ivonescimab was 17.0 months compared to 14.0 months for those receiving placebo. These findings demonstrate consistent benefits across various subgroups. Akeso has also announced that the HARMONi-A study conducted in China has reached its OS clinical endpoint, with results to be presented at future academic conferences. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN67362) on September 07, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)

### Related Stocks

- [09926.HK - AKESO](https://longbridge.com/en/quote/09926.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 康方生物报告 Cadonilimab 在一线 PD-L1 低表达胃癌研究中表现优于 PD-1 抑制剂 | 康方生物报告称，卡多利单抗联合化疗在一项针对 PD-L1 CPS  | [Link](https://longbridge.com/en/news/272494568.md) |
| 康方生物更新了合同制造安排，补充协议的到期时间设定为 2039 年 | 康方生物已更新与 CTTQ-Akeso 及其他方的合同制造安排，确认补充协议将持续至 2039 年 8 月 29 日。该协议允许根据必要性和市场条件签订新合同。单克隆抗体产品的年度采购上限是根据历史数据和市场需求设定的，定价基于制造成本加上 | [Link](https://longbridge.com/en/news/273684258.md) |
| 特朗普宣布 5500 亿日本投资正式启动，首批聚焦油气、发电、关键矿产 | 特朗普称关税促成大规模投资，三个 “大项目” 涉及得州油气战略、俄亥俄州发电和佐治亚州关键矿产领域；燃气发电厂将是 “史上最大”，墨西哥湾的 LNG 设施将推动出口并巩固美国的能源主导低地位，关键矿产设施将结束美国对外依赖。 | [Link](https://longbridge.com/en/news/276173721.md) |
| “10-15 天” 最后通牒？特朗普：美伊必须达成有意义协议，否则发生 “糟糕的事” | 周四特朗普称，预计未来十天左右知道能否与伊朗达成协议；内塔尼亚胡警告伊朗，以色列 “为任何情况做好准备”，强调以方正与美国 “并肩作战” 应对伊方威胁。国际原子能机构总干事称，美国在中东军事集结意味着，伊朗的外交窗口正在关闭。周三消息称，美 | [Link](https://longbridge.com/en/news/276394487.md) |
| 领土问题首上谈判桌 俄乌博弈进入 “深水区” | 在日内瓦举行的俄美乌三方谈判中，领土问题首次被纳入讨论议程。谈判于 2 月 17 日至 18 日进行，俄方称谈判 “务实高效”，乌方表示讨论深入且具有实质意义，美方则称各方同意继续谈判。尽管各方均表示取得进展，但关于下一轮谈判的细节尚未公布 | [Link](https://longbridge.com/en/news/276289464.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.